Trials / Unknown
UnknownNCT06174857
Efficacy of Osimertinib in Patients With Lung Cancer
Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Conditions
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2025-06-15
- Completion
- 2025-09-15
- First posted
- 2023-12-18
- Last updated
- 2023-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06174857. Inclusion in this directory is not an endorsement.